News | September 26, 2024
Biocon Biologics Global to raise funds through senior secured notes
The Notes shall not be offered or sold in India
The Notes shall not be offered or sold in India
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
